Pasithea announces activation of trial site at UAB for study of PAS-004

Pasithea Therapeutics (KTTA) announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham, UAB, for its ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. “We are pleased to activate UAB as a clinical site for our ongoing Phase 1/1b PAS-004 trial,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “UAB brings deep clinical expertise in NF1 and a strong commitment to advancing care for patients with NF1 neurofibromas. Alongside our continued engagement with the NF community, including our recent platinum sponsorship of the NF Caregivers Symposium, we remain focused on advancing PAS-004 through clinical development with urgency and purpose.”